Journal article icon

Journal article

The oncometabolite 2-hydroxyglutarate activates the mTOR signalling pathway

Abstract:

The identification of cancer-associated mutations in the tricarboxylic acid (TCA) cycle enzymes isocitrate dehydrogenases 1 and 2 (IDH1/2) highlights the prevailing notion that aberrant metabolic function can contribute to carcinogenesis. IDH1/2 normally catalyse the oxidative decarboxylation of isocitrate into α-ketoglutarate (αKG). In gliomas and acute myeloid leukaemias, IDH1/2 mutations confer gain-of-function leading to production of the oncometabolite R-2-hydroxyglutarate (2HG) from αKG...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed
Version:
Publisher's version

Actions


Access Document


Files:
Publisher copy:
10.1038/ncomms12700

Authors


Carbonneau, M More by this author
M Gagné, L More by this author
Lalonde, M-E More by this author
Germain, M-A More by this author
Motorina, A More by this author
Expand authors...
Publisher:
Springer Nature Publisher's website
Journal:
Nature Communications Journal website
Volume:
7
Pages:
Article number 12700
Publication date:
2016-09-14
Acceptance date:
2016-07-25
DOI:
EISSN:
2041-1723
Pubs id:
pubs:645849
URN:
uri:51aeee92-f67e-4d12-a0f8-c24b79c5d9d9
UUID:
uuid:51aeee92-f67e-4d12-a0f8-c24b79c5d9d9
Local pid:
pubs:645849

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP